Page last updated: 2024-12-07

2'-deoxy-2'-methylenecytidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Cross-References

ID SourceID
PubMed CID3005913
CHEMBL ID4745492
SCHEMBL ID18265
MeSH IDM0157375

Synonyms (12)

Synonym
2'-deoxy-2'-methylene cytidine
4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)-3-methylene-tetrahydrofuran-2-yl]pyrimidin-2-one
2'-deoxy-2'-methylenecytidine
2'-deoxy-2'-methylidenecytidine
cytidine, 2'-deoxy-2'-methylene-
4-amino-1-[(2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)-3-methylideneoxolan-2-yl]pyrimidin-2-one
flt15e4x9n ,
unii-flt15e4x9n
SCHEMBL18265
PULHLIOPJXPGJN-BWVDBABLSA-N
Q27278056
CHEMBL4745492

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Twice-daily dosing was associated with greater toxic effects than once-daily dosing."( Models of schedule dependent haematological toxicity of 2'-deoxy-2'-methylidenecytidine (DMDC).
Brindley, CJ; Devlin, AJ; Friberg, LE; Karlsson, MO, 2000
)
0.31

Pharmacokinetics

ExcerptReferenceRelevance
" Following intravenous administration at 30 to 450 mg/m2, DMDC has low systemic clearance (10 to 15 L/h/m2), moderate volume of distribution (nominally similar to total body water) and a short elimination half-life of between 2 and 6 hours."( Clinical pharmacokinetics of 2'-deoxy-2'-methylidenecytidine (DMDC), a deoxycytidine analogue antineoplastic agent.
Brindley, CJ; Devlin, AJ; Funaki, T; Gordon, RJ; Morrison, R; van der Gaast, A; Verweij, L, 2000
)
0.31

Bioavailability

ExcerptReferenceRelevance
" Forty to 50% of the administered dose was recovered in the urine, indicating a good bioavailability and resulting significant systemic exposure to the drug, which may enable chronic oral treatment."( Phase I trial of oral 2'-deoxy-2'-methylidenecytidine: on a daily x 14-day schedule.
Fukuoka, M; Kudoh, S; Masuda, N; Matsui, K; Myobudani, H; Nakagawa, K; Negoro, S; Nemoto, S; Nihira, S; Nogami, T; Ogawa, K; Okuda, T; Takeda, K; Takifuji, N; Yamada, M; Yamamoto, N, 2000
)
0.31
" Oral bioavailability of DMDC is in the order of 40%, largely as a result of first-pass metabolism in the gut and liver."( Clinical pharmacokinetics of 2'-deoxy-2'-methylidenecytidine (DMDC), a deoxycytidine analogue antineoplastic agent.
Brindley, CJ; Devlin, AJ; Funaki, T; Gordon, RJ; Morrison, R; van der Gaast, A; Verweij, L, 2000
)
0.31

Dosage Studied

ExcerptRelevanceReference
" Of all the tested drug dosage levels (25, 50, and 75 mg/kg, respectively) compound 23 had no toxic deaths and compound 22 yielded only one toxic death at the highest dosage level."( Synthesis and anticancer and antiviral activities of various 2'- and 3'-methylidene-substituted nucleoside analogues and crystal structure of 2'-deoxy-2'-methylidenecytidine hydrochloride.
Birnbaum, GI; Cheng, YC; Clarke-Katzenburg, RH; Gabe, EJ; Giziewicz, J; Lin, TS; Liu, MC; Luo, MZ; Mancini, WR; Prusoff, WH, 1991
)
0.28
" Given the recovery pattern for suppression of marrow, the above mentioned results led us to decide that an recommended method of administration and dosage in an early phase II trial would be 300 mg/m2 per administration by an intravenous infusion every 2 approximately 3 weeks."( [Phase I study on DMDC].
Ariyoshi, Y; Fukuoka, M; Fukuyama, E; Furue, H; Furuse, K; Gemma, A; Harada, M; Hasegawa, K; Horikoshi, N; Kanamaru, R; Kudoh, S; Kurihara, M; Kurita, Y; Mori, K; Niitani, H; Ota, K; Taguchi, T; Tsukagoshi, S; Wakui, A; Yoneda, S, 1996
)
0.29
" Several tumour responses are observed at the highest doses of DMDC, indicating a possible dose-response relationship with this drug."( Clinical pharmacokinetics of 2'-deoxy-2'-methylidenecytidine (DMDC), a deoxycytidine analogue antineoplastic agent.
Brindley, CJ; Devlin, AJ; Funaki, T; Gordon, RJ; Morrison, R; van der Gaast, A; Verweij, L, 2000
)
0.31
" Twice-daily dosing was associated with greater toxic effects than once-daily dosing."( Models of schedule dependent haematological toxicity of 2'-deoxy-2'-methylidenecytidine (DMDC).
Brindley, CJ; Devlin, AJ; Friberg, LE; Karlsson, MO, 2000
)
0.31
" One-week interruption showed sufficient recovery of decreased WBC in dosing regimens of 1-week-on/1-week-off and 2-weeks-on/2-weeks-off."( Effect of dose regimen on the toxicity of 2'-deoxy-2'-methylidenecytidine (DMDC) in monkeys.
Horii, I; Kawashima, A; Kobayashi, K; Nakano, K; Shindoh, H; Shishido, N, 2007
)
0.34
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (28)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (3.57)18.7374
1990's16 (57.14)18.2507
2000's11 (39.29)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (6.67%)5.53%
Reviews6 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other22 (73.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]